Journal of Internal Medicine Concepts & Practice >

2022 , Vol. 17 >Issue 06: 463 - 467

DOI: https://doi.org/10.16138/j.1673-6087.2022.06.008

Review article

Progress of novel antibody-like drugs in treatment of acute B lymphoblastic leukemia

Expand

Received date: 2021-03-16

  Online published: 2023-02-27

Fold

Cite this article

REN Jiayi, MI Jianqing . Progress of novel antibody-like drugs in treatment of acute B lymphoblastic leukemia[J]. Journal of Internal Medicine Concepts & Practice, 2022 , 17(06) : 463 -467 . DOI: 10.16138/j.1673-6087.2022.06.008

References

[1] Lanza F, Maffini E, Rondoni M, et al. CD22 expression in B-cell acute lymphoblastic leukemia[J]. Cancers (Basel), 2020, 12(2): 303.
[2] DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies[J]. Blood, 2004, 103(5): 1807-1814.
[3] Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia[J]. Lancet Oncol, 2012, 13(4): 403-411.
[4] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia[J]. Cancer, 2019, 125(14): 2474-2487.
[5] Short NJ, Kantarjian H, Ravandi F, et al. Updated results from a phase Ⅱstudy of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia[J]. Blood, 2021, 138 Suppl 1: 3400.
[6] Chevallier P, Leguay T, Doubek M, et al. Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy provides very good outcome in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2021, 138 Suppl 1: 511.
[7] Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro[J]. Leukemia, 2000, 14(5): 853-858.
[8] Schindler J, Gajavelli S, Ravandi F, et al. A phase Ⅰ study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia[J]. Br J Haematol, 2011, 154(4): 471-476.
[9] Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity[J]. Clin Cancer Res, 2005, 11(4): 1545-1550.
[11] Shah NN, Bhojwani D, August K, et al. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2020, 67(5): e28112.
[12] Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 24(13):2721-2729.
[13] Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study[J]. Lancet Oncol, 2019, 20(7): 998-1010.
[14] Jones L, McCalmont H, Evans K, et al. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin(SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts[J]. Pediatr Blood Cancer, 2019, 66(8): e27765.
[15] Kantarjian HM, Lioure B, Kim SK, et al. A phase Ⅱ study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2016, 16(3): 139-145.
[16] Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab[J]. Blood, 2012, 119(26): 6226-6233.
[17] Topp MS, G?ckbuget N, Stein AS. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia[J]. Lancet Oncol, 2015, 16(1): 57-66.
[18] Kantarjian H, Stein A, G?kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847.
[19] Foà R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults[J]. N Engl J Med, 2020, 383(17): 1613-1623.
[20] G?kbuget N, Stoltefu? A, Topp M, et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia(ALL)[J]. Blood, 2021, 138 Suppl 1: 3399.
[21] Nicholas J, Kantarjian H, Ravandi F, et al. Updated results from a phase Ⅱ study of hyper-CVAD with sequential blinatumomab in adults with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic leukemia[J]. Blood, 2021, 138 Suppl: 1233.
[22] Abuasab T, Rowe J, Tvito A. Emerging monoclonal antibody therapy for the treatment of acute lymphoblastic leukemia[J]. Biologics, 2021, 15: 419-431.
[23] Cremasco F, Menietti E, Speziale D, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model[J]. PLoS One, 2021, 16(1): e0241091.
Options
Outlines

/

〈 〉